Romosozumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Sclerostin |
| Clinical data | |
| Trade names | Evenity |
| Other names | AMG 785, romosozumab-aqqg |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619026 |
| License data |
|
| Pregnancy category |
|
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6452H9926N1714O2040S54 |
| Molar mass | 145877.58 g·mol−1 |
| (what is this?) (verify) | |
Romosozumab, sold under the brand name Evenity (/ɪˈvɛnɪti/ ih-VENN-ih-tee or with the pin-pen merger, /ɪˈvɪnɪti/ ih-VINN-ih-tee), is a medication used to treat osteoporosis. It has been found to decrease the risk of fractures of the spine.
Common side effects include headache, joint pain, and injection site reactions including pain. It may increase the risk of heart attacks, strokes, and deaths from cardiovascular disease. It is a humanized monoclonal antibody that targets sclerostin. Research shows the drug increases bone formation and decreases bone resorption in postmenopausal women with low bone density. Romosozumab was approved for medical use in Japan, the United States and the European Union in 2019.
The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.